Attenuated High-Dose Cytosine Arabinoside in the Treatment of the Elderly Patient with Acute Nonlymphocytic Leukemia
- 1 June 1989
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 12 (3) , 201-204
- https://doi.org/10.1097/00000421-198906000-00004
Abstract
Seventeen elderly patients with acute nonlymphocytic leukemia (EP-ANLL) were treated with cytarabine, either 1.5 g/m2 or 2.0 g/m2 q 12 h for 4 days [attenuated high-dose ARA-C (HDARAC)]. One complete and one partial response was seen in 15 evaluable cases. Toxicity, evaluated in all 17 patients, was severe, with 47% showing a variety of Eastern Cooperative Oncology Group grade 3, 4, or 5 toxicities. Forty-one percent of all patients died within 33 days of initiating treatment. We conclude that attenuated HDARAC is ineffective in inducing remission and is very toxic in the EP-ANLL.Keywords
This publication has 8 references indexed in Scilit:
- High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study.Journal of Clinical Oncology, 1987
- Low-Dose Cytosine Arabinoside in the Treatment of Relapsed and Refractory Acute Non-Lymphocytic LeukaemiaActa Haematologica, 1986
- Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly.Journal of Clinical Oncology, 1984
- Acute cerebellar dysfunction with high-dose ARA-C therapyCancer, 1983
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982
- CAUSES OF INITIAL REMISSION INDUCTION FAILURE IN ACUTE MYELOGENOUS LEUKEMIA1982
- Acute myeloblastic leukemia in elderly patients. Treatment and prognostic factorsCancer, 1980
- High dose cytosine arabinoside (HDARAC) in refractory acute leukemiaCancer, 1979